Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy

Date

21 Oct 2023

Session

Poster session 13

Topics

Tumour Site

Melanoma

Presenters

Marin Golcic

Citation

Annals of Oncology (2023) 34 (suppl_2): S651-S700. 10.1016/S0923-7534(23)01941-5

Authors

M. Golcic1, L. Simetic2, D. Herceg3, K. Blazicevic4, G. Kenđel-Jovanović5, I. Dražić6, A. Belančić7, N. Skočibušić8, D. Palčevski9, I. Rubinić8, V. Vlahović-Palčevski8, T. Majnarić10, R. Dobrila-Dintinjana11, S. Plestina12

Author affiliations

  • 1 Department For Radiotherapy And Oncology, Clinical Hospital Center Rijeka, 51000 - Rijeka/HR
  • 2 Oncology, KBC - University Hospital Centre Zagreb, 10000 - Zagreb/HR
  • 3 Department Of Oncology, KBC - University Hospital Centre Zagreb, 10000 - Zagreb/HR
  • 4 Oncology Department, KBC - University Hospital Centre Zagreb, 10000 - Zagreb/HR
  • 5 Nutrition, ZZJZ PGŽ, Rijeka/HR
  • 6 Mathematics, University of Rijeka - Faculty of Engineering, Rijeka/HR
  • 7 Pharmacology, University of Rijeka - Faculty of Medicine, 51000 - Rijeka/HR
  • 8 Pharmacology, University Hospital KBC Rijeka, 51000 - Rijeka/HR
  • 9 Allergology, University Hospital KBC Rijeka, 51000 - Rijeka/HR
  • 10 Family Medicine, Community Health Center of Primorsko-goranska County, Rijeka/HR
  • 11 Radiotherapy And Oncology Department, University Hospital KBC Rijeka, 51000 - Rijeka/HR
  • 12 Oncology Dept., KBC - University Hospital Centre Zagreb, 10000 - Zagreb/HR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1172P

Background

While immunotherapy has improved the prognosis of metastatic melanoma patients, a minority of patients will have prolonged remission. Recent data have emphasized the role of the gut microbiome in response to immunotherapy; however, there is a discrepancy in defining the optimal microbiome. Although recent fecal microbial transplantation (FMT) trials only included patients with sustained response to immunotherapy, a mixed response was registered, with scarce data on the antimicrobial resistance of the donors. A thorough evaluation of the gut microbiome of potential FMT donors is warranted before future trials.

Methods

A shotgun metagenomic sequencing was performed on Illumina NextSeq 2000 platform on stool samples of metastatic melanoma patients with complete and sustained response to immunotherapy (N=15).

Results

The average age of patients was 61.0 (±12.2) years. Patients usually received immunotherapy in the first line (N=14, 93.3%), with an average time to complete response of 7.6 (± 4.6) months. Firmicutes were the most common phylum with a relative abundance of 62.1% ± 13.2, followed by the Bacteroidetes (31.7% ± 13.8). Protobacteria were present in all patients, ranging from 0.06-3.4%. On Class level, Clostridia were the most abundant (53.9% ± 10.4), followed by Bacteroidia (31.7% ± 13.8). Similar results were seen for the order level, while Lachnospiraceae were the most common family (30.2% ± 8.6) but ranged from 8.1 – 43.8%, followed by Ruminococcaceae (6.7% ± 14.0), and Bacteroidaceae (6.2% ± 11.6). Only 14 bacterial families were present in all patients (25.4%). On the genus level, Bacteroides had the highest relative abundance (11.6% ± 6.2), followed by Lachnospiraceae (10.1% ± 5.9), and Phocaeicola (6.2% ± 4.4). 377 different species were found, with six patients (40%) reporting no traces of the Akkermansia municiphila. Antimicrobial resistance was most commonly found for tetracyclines (63.3% ± 6.9), macrolide-lincosamine-streptogramin B (14.5% ± 7.9), and sulfonamide trimethoprim (4.4% ± 2.4).

Conclusions

Patients with complete and sustained response to immunotherapy exhibit a heterogeneous gut microbiome with common resistance to Tetracycline antibiotics.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Croatian Society of Medical Oncology.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.